This year’s American Diabetes Association’s (ADA) Scientific Sessions in Orlando, Florida highlighted some important JDRF-supported research underway, encompassing breakthrough clinical trials and significant research findings that are paving the way to novel and emerging treatments for T1D.
A world first program designed to help medical researchers in type one diabetes develop their leadership skills to help take innovations out of the lab and into the real world has graduated its first intake. The graduates, announced in Canberra on June 26th 2018, have already put their skills into practice, securing funding to look at a dietary supplement that could stop type one diabetes. Read More
Two promising Australian research projects have been awarded almost $3 million in funding from The Leona M. and Harry B. Helmsley Charitable Trust, to be administered by JDRF Australia.
We are pleased to announce the recipients of the Type 1 Diabetes Clinical Research Network’s (T1DCRN) Mentored Clinician Researcher Fellowship Award (MCRF) for 2017.
The T1DCRN is an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC). One of the key objectives of the CRN is to nurture the next generation of clinical research leaders and secure the future of type 1 diabetes (T1D) research in Australia.
The international AdDIT trial group have this month published results of a four year clinical trial in The New England Journal of Medicine, finding that ACE inhibitors and statins did not change the primary outcome – the albumin to creatinine ratio – compared to placebo in adolescents with type 1 diabetes (T1D). Read More
A new study has developed a prediction tool to help clinicians predict which newly diagnosed children and adolescents are unlikely to experience a period of remission.
The remission phase, also called the honeymoon phase, is the period of time after clinical diagnosis of T1D where the body can make just enough insulin (“endogenous” insulin) to control blood glucose levels either without needing insulin injections or with significantly lower doses. Read More
International diabetes registries report that many young people with type 1 diabetes (T1D) do not meet their recommended targets for glycaemic control, however relevant Australian data has been lacking. The Australasian Diabetes Data Network (ADDN) funded by the Type 1 Diabetes Clinical Research Network (T1DCRN) and led by the Australasian Paediatric Endocrine Society (APEG) and Australian Diabetes Society (ADS) is a secure, centralised database that captures de-identified clinical data from thousands of people after diagnosis of T1D on a single purpose built database. The ADDN study group has published the first national surveillance of glycaemic control and management of type 1 diabetes in young people in Australia.
There are a number of genes linked to type 1 diabetes (T1D), but not everyone with genetic predisposition develops the condition. This suggests that there are likely environmental triggers that stimulate the development of T1D. The Environmental Determinants of Diabetes in the Young (TEDDY), a study part supported by JDRF, is a large prospective, longitudinal cohort study investigating the environmental factors that may contribute to T1D development.
An article published by the TEDDY study group in Paediatric Diabetes this month highlights the benefits of early diagnosis of children at risk of T1D. Children involved in TEDDY are from six large clinical centres across the US and Europe and are being followed from birth until 15 years of age to track diet, illness, body growth and other life experiences.
Senator The Hon Simon Birmingham, Minister for Education and Training, and The Hon Greg Hunt MP, Minister for Health and Minister for Sport, have today announced the recipients of Innovation Award grants for research into type 1 diabetes.
Three bold, promising research projects have been selected and will benefit from $4.5 million in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).
In an exciting paradigm shift that aims to accelerate patient impact, the research funded by the Innovation Award grants will explore new directions in the search for a cure for type 1 diabetes, including concepts that have never before been investigated.